Chart Events
Performance Outlook
| Previous Close | 50.87 |
| Open | 51.10 |
| Bid | 51.53 x 2200 |
| Ask | 51.47 x 3100 |
| Day's Range | 50.61 - 51.71 |
| 52 Week Range | 33.36 - 54.94 |
| Volume | 32,316,938 |
| Avg. Volume | 30,939,449 |
| Market Cap | 287.777B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 26.04 |
| EPS (TTM) | 1.97 |
| Earnings Date | Jan 31, 2022 - Feb 04, 2022 |
| Forward Dividend & Yield | 1.56 (3.98%) |
| Ex-Dividend Date | Jul 29, 2021 |
| 1y Target Est | 46.23 |
- Investor's Business Daily
Dow Jones Futures: Market Rally Awaits Omicron Variant News After Covid Sell-Off; What To Do Now
Fears of the new Omicron Covid variant slammed the stock market Friday. Here's what investors should do now. Li Auto earnings are on tap.
- Investor's Business Daily
Dow Jones Futures: Covid Variant Fears Slam Market Rally, What To Do; Tesla Rival Li Auto Due
Fears of the new Omicron Covid variant slammed the stock market Friday. Here's what investors should be doing now. Li Auto earnings are on tap.
- Barrons.com
Covid Testing Company Says PCR Tests Are Effective Against New Covid Variant
Qiagen closed higher Friday after the diagnostics company reaffirmed the efficacy of its PCR tests against the new Covid variant which scrambled stock markets on Friday. Qiagen (ticker: QGEN) said it assessed its SARS-CoV-2 PCR tests against the new genetic mutations of the variant, known by its scientific name, B.1.1.529. “We are pleased to report that the emergence of this new variant of concerns, as has been the case with other variants, has had no impact on the effectiveness of our SARS-CoV-2 PCR tests,” said Davide Manissero, chief medical officer at Qiagen.
